Effects of a PAF Receptor Antagonist on Airway Inflammation in Asthma
Author Information
Author(s): R. H. Gundel, C. D. Wegner, H. O. Heuer, L. G. Letts
Primary Institution: Boehringer Ingelheim Pharmaceuticals, Inc.
Hypothesis
Does the PAF receptor antagonist WEB 2170 affect acute and chronic airway inflammation in a primate model of allergic asthma?
Conclusion
WEB 2170 effectively reduces acute airway inflammation but does not impact chronic airway inflammation or hyperresponsiveness.
Supporting Evidence
- WEB 2170 inhibited the release of leukotriene C4 and prostaglandin D2 during acute airway inflammation.
- WEB 2170 blocked the acute influx of neutrophils into the airways.
- Multiple dosing of WEB 2170 did not reduce chronic airway inflammation or hyperresponsiveness.
Takeaway
A medicine called WEB 2170 helps with sudden asthma attacks but doesn't help with long-term asthma problems.
Methodology
The study used wild caught, adult male cynomolgus monkeys to assess the effects of WEB 2170 on airway inflammation and function.
Limitations
The study did not assess the long-term effects of higher doses or more frequent dosing of WEB 2170.
Participant Demographics
Wild caught, adult male cynomolgus monkeys (Macaca fascicularis) weighing 3.5-7.5 kg.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website